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measurements. However, no relevant relation 
was highlighted between all the tested biomark‑
ers (hs ‑CRP, N ‑terminal pro B‑type natriuret‑
ic peptide [NT ‑proBNP], growth differentiation 
factor 15 [GDF‑15], galectin 3, renalase, and co‑
peptin) and the 4‑week efficacy of CVE.5
Although the  small study sample and 
the monocentric setting limit the generaliza‑
tion of the results, the present study5 enriches 
the open debate on the practical utility of bio‑
markers in the AF population.
As we know, AF pathophysiology articulates 
on a complex interplay between atrial remod‑
elling (atrial enlargement and fibrosis), inflam‑
matory substrate, and oxidative stress. All these 
factors are entwined in a bidirectional relation 
in which each one influences others’ appear‑
ance, maintenance, and arrhythmia progres‑
sion. Nowadays, the recommended approach to 
AF management is a holistic and integrated pro‑
cess that encompasses both patient and arrhyth‑
mia characteristics, in line with an individual‑
‑oriented clinical model resumed by the ABC 
approach (A, avoid stroke; B, better symptoms 
control; C, cardiovascular and comorbidity risk 
factor control).6 From this perspective, and due 
to their dynamic nature, biomarkers may serve 
as an extra tool for an individualized decision‑
‑making process with the aim to provide a more 
targeted care.7
Many biomarkers have been evaluated with 
these purposes, from traditional markers of in‑
flammation or atrial stretching (hs ‑CRP, NT‑
‑proBNP) and routinely available assays (eg, red 
blood cell distribution width [RDW])8 to ex‑
tremely specific tests not currently employed 
The way we look at atrial fibrillation (AF) has rad‑
ically changed in the last decade, switching from 
a mere arrhythmic conception to a complex no‑
sological entity subtending structural and ultra‑
structural cardiac changes.1 Together with this 
acquisition, the concept of atrial cardiomyopa‑
thy has progressively matured and several cir‑
culating factors have been identified as mark‑
ers of atrial disease and, by association, are as‑
sumed to be reliable in AF clinical assessment.2
However, despite the undebatable usefulness 
of biomarkers in many settings, their exces‑
sive or inappropriate use can lead to unneces‑
sary and even harmful procedures as well as 
to a waste of healthcare resources. Thus, given 
the increasing number of available biomarkers 
and their several possible clinical applications, 
there is a need to clarify which ones are clin‑
ically effective and cost effective at the same 
time, and can substantially optimize the clin‑
ical decision ‑making process even in busy dai‑
ly settings, representing a valuable “add ‑on” to 
physicians’ practice (Figure 1).3,4
In the present issue of Kardiologia Polska (Kar-
diol Pol, Polish Heart Journal), Cichoń et al5 aimed 
to evaluate the  impact of basal and 4‑week 
follow ‑up concentrations of biomarkers of left 
atrial overload on electrical cardioversion (CVE) 
efficacy. The study population included 82 pa‑
tients with persistent AF undergoing successful 
CVE and was divided into an obese and nonobese 
group with no significative difference in the dis‑
tribution of the main features. Increased high‑
‑sensitivity C ‑reactive protein (hs ‑CRP) levels 
were found in the obese compared with the non‑
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Thus, a  question spontaneously arises: 
would a biomarker really change the daily 
management of AF patients? While research 
on biomarkers certainly contributes to un‑
cover pathophysiologic aspects that lead us 
to a deeper comprehension of the arrhythmic 
substrate and its clinical manifestations, to 
date, no circulating factor alone seems to be 
able to substantially tip the balance in the clin‑
ical decision ‑making process, neither for pa‑
tient rule ‑in nor rule ‑out.
In the  setting of AF, the  potential value 
of combining several biomarkers in order to 
achieve an integrated assessment is still not 
fully established, as well as the precise impact 
of sex, age, and ethnicity on thresholds for spe‑
cific decisions and interventions. To date, evi‑
dence supporting their role in guiding a clini‑
cians’ decision ‑making process is controver‑
sial, thus the clinical ‑based evaluation, pivot‑
ed on the medical history, physical examina‑
tion, 12‑lead electrocardiography, and cardiac 
imaging reports, remains the cornerstone of 
AF assessment.3,5,6,14
In conclusion, additional knowledge is need‑
ed to provide a daily clinical approach based on 
precision medicine and including biomarkers as 
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or accessible (eg, peptides from collagen sub‑
types, micro RNAs, nucleosomes, etc).
In the AF setting, biomarkers already en‑
tered some integrated risk scores for stroke 
and bleeding prediction (ABC ‑stroke, ATRIA, 
and ABC ‑bleeding), adding a modest, albeit 
statistically significant, improvement to con‑
ventional clinical ‑based scores and with a net 
clinical advantage limited to selected cases.9 
Moreover, individual biomarkers cannot pre‑
dict specific outcomes per se, and the need 
to integrate them with clinical items may 
lead to a further complication rather than 
simplification of clinical decision making. 
On the other hand, the actual evidence on 
biomarkers’ role in predicting AF recurrenc‑
es / progression is not homogenous and is of‑
ten conflicting. In a large retrospective cohort 
of 1410 patients undergoing catheter abla‑
tion, BNP, hs ‑CRP, and estimated glomerular 
filtration rate were independent predictors 
of AF relapse after ablation with incremen‑
tal predicting value when combining all 3 
markers.10 Similarly, in a smaller cohort of 
patients with AF, Carballo et al11 found that 
basal values of hs ‑CRP and an immediate pos‑
tablation assessment of NT ‑proBNP were re‑
lated to a higher risk of AF recurrences, sup‑
porting the role of inflammation in trigger‑
ing AF pathogenesis and relapse. Conversely, 
in other studies, no significant relationships 
were found between basal concentrations of 
various biomarkers and AF recurrences.12 It 
is noteworthy that Merino ‑Merino et al13 re‑
cently proposed that follow ‑up assessments 
rather than basal measurements may reflect 
those pathophysiological changes related to 





































Type of biomarker Clinical applicability in AF
Thrombotic risk assessment
Bleeding risk assessment
Marker of underlying 
cardiac disease
Prediction of AF recurrences
Prediction of AF progression
Prediction of hospitalization
Prediction of mortality and 
CV adverse events
Patient targeting for AF 
screening
Prediction of POAF
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